Biohaven's spinal muscular atrophy drug fails to meet main goal in study
25/11/2024 12:43
Nov 25 (Reuters) - Biohaven BHVN.N said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve statistical significance compared to placebo and standard of care. (Reporting by Mariam Sunny in Bengaluru; Editing by Arun Koyyur) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing